Our data demonstrate that accumulation of ROS related to MAO-B activity not only plays a crucial role in the loss of cell viability and contractile impairment of dystrophic skeletal muscles but also in the mitochondrial dysfunction occurring in DMD myogenic cultures, thereby pointing at safinamide as a promising candidate for DMD therapy. This evidence concerns the gene MAOB and Duchenne muscular dystrophy.